28.67
                                            前日終値:
              $28.95
            開ける:
              $28.55
            24時間の取引高:
                2.81M
            Relative Volume:
              1.44
            時価総額:
                $18.39B
            収益:
              $2.62B
            当期純損益:
              $966.70M
            株価収益率:
              19.11
            EPS:
                1.5004
            ネットキャッシュフロー:
                $1.09B
            1週間 パフォーマンス:
              -4.02%
            1か月 パフォーマンス:
              -2.25%
            6か月 パフォーマンス:
                +37.90%
            1年 パフォーマンス:
              +27.03%
            Genmab Adr Stock (GMAB) Company Profile
GMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                GMAB
                            
                             Genmab Adr | 28.67 | 17.82B | 2.62B | 966.70M | 1.09B | 1.5004 | 
|   
                          
                                VRTX
                            
                             Vertex Pharmaceuticals Inc | 419.89 | 106.97B | 11.39B | 3.64B | 3.50B | 13.99 | 
|   
                          
                                REGN
                            
                             Regeneron Pharmaceuticals Inc | 654.04 | 68.62B | 14.25B | 4.58B | 3.88B | 41.77 | 
|   
                          
                                ALNY
                            
                             Alnylam Pharmaceuticals Inc | 449.56 | 63.13B | 2.46B | -319.09M | -52.09M | -2.4669 | 
|   
                          
                                ARGX
                            
                             Argen X Se Adr | 820.36 | 50.61B | 3.06B | 1.28B | 447.35M | 19.67 | 
|   
                          
                                INSM
                            
                             Insmed Inc | 194.22 | 35.29B | 398.11M | -1.03B | -868.57M | -5.7032 | 
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 | 
|---|---|---|---|
| 2025-09-23 | アップグレード | Guggenheim | Neutral → Buy | 
| 2025-04-01 | ダウングレード | Bernstein | Mkt Perform → Underperform | 
| 2025-03-11 | アップグレード | William Blair | Mkt Perform → Outperform | 
| 2025-02-13 | アップグレード | Leerink Partners | Market Perform → Outperform | 
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy | 
| 2024-09-04 | 再開されました | Morgan Stanley | Equal-Weight | 
| 2024-08-20 | ダウングレード | JP Morgan | Overweight → Neutral | 
| 2024-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform | 
| 2024-02-23 | アップグレード | BMO Capital Markets | Market Perform → Outperform | 
| 2024-01-22 | ダウングレード | Citigroup | Neutral → Sell | 
| 2023-12-06 | アップグレード | UBS | Neutral → Buy | 
| 2023-11-10 | アップグレード | Deutsche Bank | Hold → Buy | 
| 2023-11-08 | アップグレード | DNB Markets | Sell → Buy | 
| 2023-10-18 | 開始されました | Exane BNP Paribas | Underperform | 
| 2023-09-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform | 
| 2023-08-24 | 開始されました | BTIG Research | Buy | 
| 2023-07-14 | 開始されました | HSBC Securities | Buy | 
| 2023-05-31 | 開始されました | UBS | Neutral | 
| 2023-05-12 | 開始されました | Morgan Stanley | Underweight | 
| 2022-12-20 | ダウングレード | Citigroup | Buy → Neutral | 
| 2022-11-14 | 開始されました | William Blair | Mkt Perform | 
| 2022-11-11 | ダウングレード | Deutsche Bank | Buy → Hold | 
| 2022-06-24 | 開始されました | BMO Capital Markets | Market Perform | 
| 2022-05-02 | 開始されました | Cowen | Market Perform | 
| 2022-03-16 | アップグレード | UBS | Neutral → Buy | 
| 2022-01-31 | アップグレード | H.C. Wainwright | Neutral → Buy | 
| 2022-01-03 | ダウングレード | Guggenheim | Buy → Neutral | 
| 2021-12-01 | 開始されました | Berenberg | Sell | 
| 2021-09-16 | ダウングレード | Jefferies | Buy → Hold | 
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight | 
| 2021-08-24 | ダウングレード | H.C. Wainwright | Buy → Neutral | 
| 2021-04-20 | 開始されました | Deutsche Bank | Buy | 
| 2021-01-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight | 
| 2020-09-23 | ダウングレード | Bryan Garnier | Neutral → Sell | 
| 2020-09-08 | 開始されました | SVB Leerink | Mkt Perform | 
| 2020-06-25 | ダウングレード | Credit Suisse | Outperform → Neutral | 
| 2020-04-23 | 開始されました | Credit Suisse | Outperform | 
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy | 
| 2020-01-13 | 開始されました | SunTrust | Buy | 
| 2019-12-12 | ダウングレード | Deutsche Bank | Buy → Hold | 
| 2019-09-13 | アップグレード | BofA/Merrill | Neutral → Buy | 
| 2019-09-12 | アップグレード | JP Morgan | Neutral → Overweight | 
| 2019-08-12 | 開始されました | Guggenheim | Buy | 
| 2019-08-12 | 開始されました | Morgan Stanley | Overweight | 
| 2019-08-12 | 開始されました | RBC Capital Mkts | Outperform | 
                    すべてを表示
                     
                  
                Genmab Adr (GMAB) 最新ニュース
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Ingalls & Snyder LLC - MarketBeat
Short Interest in Genmab A/S Sponsored ADR (NASDAQ:GMAB) Increases By 59.3% - MarketBeat
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
HC Wainwright Has Pessimistic View of Genmab A/S Q2 Earnings - Defense World
Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright - Defense World
Truist Financial Corp Reduces Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab A/S FY2026 EPS Estimate Reduced by Leerink Partnrs - Defense World
GMAB or TECH: Which Is the Better Value Stock Right Now? - sharewise.com
CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight - GlobeNewswire Inc.
Q3 EPS Estimates for Genmab A/S Lowered by Leerink Partnrs - MarketBeat
31,681 Shares in Genmab A/S Sponsored ADR $GMAB Purchased by Callan Family Office LLC - MarketBeat
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
William Blair Brokers Lift Earnings Estimates for Genmab A/S - MarketBeat
DAVENPORT & Co LLC Grows Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Wealth Enhancement Advisory Services LLC Buys New Shares in Genmab A/S Sponsored ADR $GMAB - Defense World
QRG Capital Management Inc. Sells 8,945 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighHere's Why - MarketBeat
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - sharewise.com
Genmab AS (GMAB) Stock Price, Trades & News - GuruFocus
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? - sharewise.com
Why Genmab Stock Popped on Friday - The Globe and Mail
Leerink Partnrs Weighs in on Genmab A/S FY2027 Earnings - Defense World
Best Momentum Stock to Buy for October 3rd - sharewise.com
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $40.00 at HC Wainwright - Defense World
Genmab A/S Sponsored ADR $GMAB Stock Position Lowered by Signaturefd LLC - Defense World
New Strong Buy Stocks for October 3rd - Yahoo Finance
Leerink Partnrs Comments on Genmab A/S FY2027 Earnings - MarketBeat
Genmab A/S Updates Articles of Association to Enhance Growth Strategy - The Globe and Mail
FY2025 EPS Estimates for Genmab A/S Boosted by William Blair - MarketBeat
Park Avenue Securities LLC Acquires 832 Shares of Genmab A/S Sponsored ADR $GMAB - Defense World
TD Cowen Remains a Hold on Genmab (GMAB) - The Globe and Mail
Genmab A/S (NASDAQ:GMAB) Sets New 52-Week HighWhat's Next? - MarketBeat
TD Private Client Wealth LLC Has $130,000 Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume on Analyst Upgrade - Defense World
Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Trending tickers: Alibaba, AstraZeneca, GSK, Stellantis and Genmab - Yahoo
European Stocks Higher to Kick Off the Week - TradingView
Genmab Adr (GMAB) 財務データ
収益
当期純利益
現金流量
EPS
                大文字化:
                 
                  | 
                ボリューム (24 時間):
                 
            
         
                     
                             ストックスクリーナーアプリを入手
                    ストックスクリーナーアプリを入手